MAPK3 and renal cell carcinoma: It was recently reported that serum concentration of HGF, the c-Met receptor ligand, was significantly elevated in renal cell carcinoma (RCC) patients compared to healthy individuals, thereby suggesting that miR-199a-3p impairs HGF/c-Met signaling pathway, including STAT3, mTOR and ERK1/2, which is crucial for RCC development, thus also suggesting that this miR may serve as a potential target for RCC therapy [29].